Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA? (Pembrolizumab) in Selected Advanced Solid Tumors

San Diego Biotechnology Network
San Diego Biotechnology Network
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA? (Pembrolizumab) in Selected Advanced Solid Tumors
Loading
/

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamer?s investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Merck?s anti-PD-1 therapy, KEYTRUDA? (pembrolizumab) in patients with selected advanced solid tumors. Collaboration with Merck Under